Enrico Petrillo


Dr. Petrillo is an international leader in healthcare innovation in life sciences and IT with decades of experience as a venture capitalist, strategy consultant, academic physician, founder, and national policy advisor. He is director of international research programs and strategic initiatives for Harvard's flagship teaching hospital, Brigham and Women’s Hospital (BWH), and senior advisor to the Chair Dept. of Medicine and Physician-in-Chief. He is a faculty lecturer at Harvard Medical School, principal investigator in the Dept. of Medicine, and faculty-affiliated researcher at the Karolinska Institutet Sweden.

Enrico co-founded two early-stage institutional venture capital firms, with multiple funds under management totaling several hundred million dollars each. Representative investments include global leading platforms in cancer diagnostics and screening, precision cancer therapeutics, Life Sciences tools, healthcare cybersecurity, health and wellbeing, transplantation, women's health, and Healthcare IT. During his tenure at FletcherSpaght Inc. (FSI), a Boston Consulting Group spin-out specializing in innovation and technology advice, Enrico led the initiation and development of world-leading innovation centers for Harvard teaching hospitals BWH and Boston Children’s Hospital. He consummated multiple high-profile technology transfer transactions, Including the commercialization of the world’s first cancer portfolio of cancer angiogenesis therapies, including Thalidomide, leading to Celgene being acquired by Bristol M Squibb for $69B; this breakthrough has spawned an entire leading field of cancer treatments worldwide.

Enrico has served as a national policy advisor to United States presidential candidates, senate members, and governmental agencies.